QIAGEN N.V. (QGEN) Fundamental Analysis & Valuation

NYSE:QGEN • NL0015002SN0

Current stock price

34.02 USD
-4.07 (-10.69%)
At close:
34.12 USD
+0.1 (+0.29%)
Pre-Market:

This QGEN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. QGEN Profitability Analysis

1.1 Basic Checks

  • QGEN had positive earnings in the past year.
  • In the past year QGEN had a positive cash flow from operations.
  • In the past 5 years QGEN has always been profitable.
  • In the past 5 years QGEN always reported a positive cash flow from operatings.
QGEN Yearly Net Income VS EBIT VS OCF VS FCFQGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

1.2 Ratios

  • The Return On Assets of QGEN (6.76%) is better than 84.21% of its industry peers.
  • QGEN has a Return On Equity of 11.25%. This is amongst the best in the industry. QGEN outperforms 84.21% of its industry peers.
  • QGEN has a better Return On Invested Capital (7.25%) than 80.70% of its industry peers.
  • QGEN had an Average Return On Invested Capital over the past 3 years of 7.27%. This is below the industry average of 11.01%.
Industry RankSector Rank
ROA 6.76%
ROE 11.25%
ROIC 7.25%
ROA(3y)4.6%
ROA(5y)5.78%
ROE(3y)7.52%
ROE(5y)10.26%
ROIC(3y)7.27%
ROIC(5y)8.26%
QGEN Yearly ROA, ROE, ROICQGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15

1.3 Margins

  • With an excellent Profit Margin value of 20.33%, QGEN belongs to the best of the industry, outperforming 92.98% of the companies in the same industry.
  • In the last couple of years the Profit Margin of QGEN has remained more or less at the same level.
  • The Operating Margin of QGEN (25.71%) is better than 96.49% of its industry peers.
  • In the last couple of years the Operating Margin of QGEN has declined.
  • QGEN has a Gross Margin of 62.99%. This is amongst the best in the industry. QGEN outperforms 84.21% of its industry peers.
  • QGEN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 25.71%
PM (TTM) 20.33%
GM 62.99%
OM growth 3Y-0.65%
OM growth 5Y-1.69%
PM growth 3Y0.95%
PM growth 5Y1.14%
GM growth 3Y-0.51%
GM growth 5Y-0.69%
QGEN Yearly Profit, Operating, Gross MarginsQGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

7

2. QGEN Health Analysis

2.1 Basic Checks

  • QGEN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, QGEN has less shares outstanding
  • The number of shares outstanding for QGEN has been reduced compared to 5 years ago.
  • The debt/assets ratio for QGEN is higher compared to a year ago.
QGEN Yearly Shares OutstandingQGEN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
QGEN Yearly Total Debt VS Total AssetsQGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

2.2 Solvency

  • An Altman-Z score of 3.19 indicates that QGEN is not in any danger for bankruptcy at the moment.
  • QGEN has a better Altman-Z score (3.19) than 71.93% of its industry peers.
  • QGEN has a debt to FCF ratio of 3.70. This is a good value and a sign of high solvency as QGEN would need 3.70 years to pay back of all of its debts.
  • With a decent Debt to FCF ratio value of 3.70, QGEN is doing good in the industry, outperforming 75.44% of the companies in the same industry.
  • A Debt/Equity ratio of 0.44 indicates that QGEN is not too dependend on debt financing.
  • QGEN has a Debt to Equity ratio (0.44) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF 3.7
Altman-Z 3.19
ROIC/WACC0.87
WACC8.35%
QGEN Yearly LT Debt VS Equity VS FCFQGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.3 Liquidity

  • A Current Ratio of 3.90 indicates that QGEN has no problem at all paying its short term obligations.
  • The Current ratio of QGEN (3.90) is better than 66.67% of its industry peers.
  • QGEN has a Quick Ratio of 3.31. This indicates that QGEN is financially healthy and has no problem in meeting its short term obligations.
  • QGEN's Quick ratio of 3.31 is fine compared to the rest of the industry. QGEN outperforms 64.91% of its industry peers.
Industry RankSector Rank
Current Ratio 3.9
Quick Ratio 3.31
QGEN Yearly Current Assets VS Current LiabilitesQGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

4

3. QGEN Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 5.09% over the past year.
  • Measured over the past 5 years, QGEN shows a small growth in Earnings Per Share. The EPS has been growing by 0.60% on average per year.
  • QGEN shows a small growth in Revenue. In the last year, the Revenue has grown by 5.65%.
  • QGEN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.25% yearly.
EPS 1Y (TTM)5.09%
EPS 3Y-2.23%
EPS 5Y0.6%
EPS Q2Q%-3.44%
Revenue 1Y (TTM)5.65%
Revenue growth 3Y-0.81%
Revenue growth 5Y2.25%
Sales Q2Q%3.69%

3.2 Future

  • The Earnings Per Share is expected to grow by 7.75% on average over the next years.
  • Based on estimates for the next years, QGEN will show a small growth in Revenue. The Revenue will grow by 7.04% on average per year.
EPS Next Y5.3%
EPS Next 2Y7.94%
EPS Next 3Y8.61%
EPS Next 5Y7.75%
Revenue Next Year6.7%
Revenue Next 2Y6.2%
Revenue Next 3Y6.16%
Revenue Next 5Y7.04%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
QGEN Yearly Revenue VS EstimatesQGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B 2B 2.5B
QGEN Yearly EPS VS EstimatesQGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1 2 3

6

4. QGEN Valuation Analysis

4.1 Price/Earnings Ratio

  • QGEN is valuated correctly with a Price/Earnings ratio of 13.77.
  • Compared to the rest of the industry, the Price/Earnings ratio of QGEN indicates a rather cheap valuation: QGEN is cheaper than 92.98% of the companies listed in the same industry.
  • QGEN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.91.
  • With a Price/Forward Earnings ratio of 13.07, QGEN is valued correctly.
  • Based on the Price/Forward Earnings ratio, QGEN is valued cheaply inside the industry as 94.74% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of QGEN to the average of the S&P500 Index (21.99), we can say QGEN is valued slightly cheaper.
Industry RankSector Rank
PE 13.77
Fwd PE 13.07
QGEN Price Earnings VS Forward Price EarningsQGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of QGEN indicates a rather cheap valuation: QGEN is cheaper than 94.74% of the companies listed in the same industry.
  • 87.72% of the companies in the same industry are more expensive than QGEN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 15.68
EV/EBITDA 9.99
QGEN Per share dataQGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates QGEN does not grow enough to justify the current Price/Earnings ratio.
  • The decent profitability rating of QGEN may justify a higher PE ratio.
PEG (NY)2.6
PEG (5Y)22.97
EPS Next 2Y7.94%
EPS Next 3Y8.61%

3

5. QGEN Dividend Analysis

5.1 Amount

  • With a yearly dividend of 0.69%, QGEN is not a good candidate for dividend investing.
  • The stock price of QGEN dropped by -36.61% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
  • Compared to an average industry Dividend Yield of 0.11, QGEN pays a better dividend. On top of this QGEN pays more dividend than 96.49% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, QGEN's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.69%

5.2 History

  • QGEN is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
QGEN Yearly Dividends per shareQGEN Yearly Dividends per shareYearly Dividends per share 2024 2025 0.2 0.4 0.6 0.8 1

5.3 Sustainability

  • QGEN pays out 12.77% of its income as dividend. This is a sustainable payout ratio.
DP12.77%
EPS Next 2Y7.94%
EPS Next 3Y8.61%
QGEN Yearly Income VS Free CF VS DividendQGEN Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M
QGEN Dividend Payout.QGEN Dividend Payout, showing the Payout Ratio.QGEN Dividend Payout.PayoutRetained Earnings

QGEN Fundamentals: All Metrics, Ratios and Statistics

QIAGEN N.V.

NYSE:QGEN (4/28/2026, 8:04:00 PM)

Premarket: 34.12 +0.1 (+0.29%)

34.02

-4.07 (-10.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Industry Strength12.16
Industry Growth92
Earnings (Last)02-05
Earnings (Next)05-04
Inst Owners75.98%
Inst Owner Change-0.97%
Ins Owners0.46%
Ins Owner ChangeN/A
Market Cap7.01B
Revenue(TTM)2.09B
Net Income(TTM)424.88M
Analysts72.5
Price Target55.29 (62.52%)
Short Float %2.83%
Short Ratio3.26
Dividend
Industry RankSector Rank
Dividend Yield 0.69%
Yearly Dividend0.25
Dividend Growth(5Y)N/A
DP12.77%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.46%
Min EPS beat(2)-3.03%
Max EPS beat(2)2.11%
EPS beat(4)2
Avg EPS beat(4)1.12%
Min EPS beat(4)-3.03%
Max EPS beat(4)7.8%
EPS beat(8)5
Avg EPS beat(8)1.49%
EPS beat(12)7
Avg EPS beat(12)1.45%
EPS beat(16)11
Avg EPS beat(16)3.7%
Revenue beat(2)0
Avg Revenue beat(2)-0.52%
Min Revenue beat(2)-0.72%
Max Revenue beat(2)-0.31%
Revenue beat(4)1
Avg Revenue beat(4)0.07%
Min Revenue beat(4)-0.72%
Max Revenue beat(4)1.43%
Revenue beat(8)1
Avg Revenue beat(8)-0.61%
Revenue beat(12)1
Avg Revenue beat(12)-0.7%
Revenue beat(16)5
Avg Revenue beat(16)-0.05%
PT rev (1m)-0.11%
PT rev (3m)2.06%
EPS NQ rev (1m)-0.7%
EPS NQ rev (3m)-6.38%
EPS NY rev (1m)0.1%
EPS NY rev (3m)-3.61%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.59%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.58%
Valuation
Industry RankSector Rank
PE 13.77
Fwd PE 13.07
P/S 3.35
P/FCF 15.68
P/OCF 10.71
P/B 1.86
P/tB 10.14
EV/EBITDA 9.99
EPS(TTM)2.47
EY7.26%
EPS(NY)2.6
Fwd EY7.65%
FCF(TTM)2.17
FCFY6.38%
OCF(TTM)3.18
OCFY9.33%
SpS10.14
BVpS18.33
TBVpS3.35
PEG (NY)2.6
PEG (5Y)22.97
Graham Number31.9207 (-6.17%)
Profitability
Industry RankSector Rank
ROA 6.76%
ROE 11.25%
ROCE 9.31%
ROIC 7.25%
ROICexc 8.95%
ROICexgc 26.41%
OM 25.71%
PM (TTM) 20.33%
GM 62.99%
FCFM 21.4%
ROA(3y)4.6%
ROA(5y)5.78%
ROE(3y)7.52%
ROE(5y)10.26%
ROIC(3y)7.27%
ROIC(5y)8.26%
ROICexc(3y)9.11%
ROICexc(5y)10.64%
ROICexgc(3y)30.34%
ROICexgc(5y)44.67%
ROCE(3y)9.34%
ROCE(5y)10.61%
ROICexgc growth 3Y-15.51%
ROICexgc growth 5Y-0.67%
ROICexc growth 3Y-7.24%
ROICexc growth 5Y0.13%
OM growth 3Y-0.65%
OM growth 5Y-1.69%
PM growth 3Y0.95%
PM growth 5Y1.14%
GM growth 3Y-0.51%
GM growth 5Y-0.69%
F-Score6
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF 3.7
Debt/EBITDA 2.26
Cap/Depr 106.91%
Cap/Sales 9.91%
Interest Coverage 18.37
Cash Conversion 89.51%
Profit Quality 105.25%
Current Ratio 3.9
Quick Ratio 3.31
Altman-Z 3.19
F-Score6
WACC8.35%
ROIC/WACC0.87
Cap/Depr(3y)90.15%
Cap/Depr(5y)87.64%
Cap/Sales(3y)8.95%
Cap/Sales(5y)8.6%
Profit Quality(3y)264.36%
Profit Quality(5y)202.24%
High Growth Momentum
Growth
EPS 1Y (TTM)5.09%
EPS 3Y-2.23%
EPS 5Y0.6%
EPS Q2Q%-3.44%
EPS Next Y5.3%
EPS Next 2Y7.94%
EPS Next 3Y8.61%
EPS Next 5Y7.75%
Revenue 1Y (TTM)5.65%
Revenue growth 3Y-0.81%
Revenue growth 5Y2.25%
Sales Q2Q%3.69%
Revenue Next Year6.7%
Revenue Next 2Y6.2%
Revenue Next 3Y6.16%
Revenue Next 5Y7.04%
EBIT growth 1Y8.54%
EBIT growth 3Y-1.45%
EBIT growth 5Y0.51%
EBIT Next Year39.59%
EBIT Next 3Y17.75%
EBIT Next 5Y12.5%
FCF growth 1Y-10.97%
FCF growth 3Y-7.55%
FCF growth 5Y23.83%
OCF growth 1Y-2.85%
OCF growth 3Y-2.92%
OCF growth 5Y7.4%

QIAGEN N.V. / QGEN Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for QIAGEN N.V.?

ChartMill assigns a fundamental rating of 6 / 10 to QGEN.


Can you provide the valuation status for QIAGEN N.V.?

ChartMill assigns a valuation rating of 6 / 10 to QIAGEN N.V. (QGEN). This can be considered as Fairly Valued.


How profitable is QIAGEN N.V. (QGEN) stock?

QIAGEN N.V. (QGEN) has a profitability rating of 7 / 10.


What are the PE and PB ratios of QIAGEN N.V. (QGEN) stock?

The Price/Earnings (PE) ratio for QIAGEN N.V. (QGEN) is 13.77 and the Price/Book (PB) ratio is 1.86.


What is the financial health of QIAGEN N.V. (QGEN) stock?

The financial health rating of QIAGEN N.V. (QGEN) is 7 / 10.